Company Name
Drug
Event
Outcome
Details
Catalyst Pharmaceutical Partners Inc.
(CPRX)
Firdapse (sNDA)
Q4 2022
FDA decision on Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) pediatric patients
FDA approved Firdapse for the treatment of Lambert-Eaton myasthenic syndrome in pediatric patients on Sep.29, 2022-
AstraZeneca PLC
(AZN.L, AZN)
Tremelimumab(BLA)
Q4 2022
FDA decision on Tremelimumab in combination with Imfinzi for the treatment of patients with unresectable hepatocellular carcinoma
-
Sanofi
( SNYNF, SNY)
Xenpozyme (BLA)
10/03/2022
FDA decision on Xenpozyme for the treatment of acid sphingomyelinase deficiency
FDA approved Xenpozyme for the treatment of acid sphingomyelinase deficiency on Aug.31, 2022-
Read More Get Access to Premium FDA Calendar with RTT Biotech Investor.